This information will be shared with Satellos representatives at the PPMD conference in Las Vegas, June 18-21, 2025.

To: Satellos Bioscience Inc.
Subject: Request for Clinical Trial Access or Compassionate Use of SAT-3247 in Malaysia and Southeast Asia

Dear Satellos Team,

We, the undersigned parents, caregivers, families and friends of children affected by Duchenne muscular dystrophy (DMD), write to express our united support for your important work and our heartfelt hope for access to SAT-3247 — a therapy that holds great promise for children and families worldwide.

This petition is being delivered by Catherine Jayasuriya, Founder and Executive Director of Coalition Duchenne, advocate, and mother of a young man living with Duchenne. She represents families from Malaysia and throughout Southeast Asia who are seeking access to emerging therapies and inclusion in global clinical trials.

At present, many families in our region lack access to clinical trials or investigational therapies. However, Malaysia is home to excellent medical institutions, including the University Malaya Medical Centre (UMMC) and Hospital Kuala Lumpur (HKL), both of which are well-positioned to support clinical research and compassionate access programs.

We respectfully request that Satellos:

- Consider Malaysia as a clinical trial site in future phases of SAT-3247;  
- Explore compassionate use or expanded access programs for children who currently have no viable treatment options; and  
- Acknowledge and respond to the families who have reached out to express their interest and hope.

We believe SAT-3247 could be transformative for the Duchenne community. We stand together — not only for our own children, but for all those in the region — in seeking equitable access to this innovative therapy.

Thank you for your vision and commitment. We support your mission, and we continue to hold hope for a brighter future.

With sincere appreciation,  
Delivered by:  
Catherine Jayasuriya  
Founder and Executive Director  
Coalition Duchenne

Cell: 714 801 4616